Outcome of patients with primary pulmonary hypertension after listing for transplantation: benefits of therapy with iloprost and bosentan

Advances in medical treatment for primary pulmonary hypertension (PPH) have improved both short- and long-term outcome of patients. However, for end-stage PPH there is controversy about long-term efficiency of this treatment and its reliability for patient withdrawal from the list for lung or heart-lung transplantation (Tx). We evaluated the benefits and safety of iloprost (prostacyclin analog) and bosentan (endothelin-receptor antagonist) in patients with end-stage PPH before and after Tx-listing. Methods: We evaluated all end-stage PPH patients (NYHA class: late III-IV) referred between 1/1996 and 6/2004 for T…